Stanford sues Natera over transplant testing patents

Stanford University has accused genetic testing company Natera of infringing two patents that cover a non-invasive method of testing if transplanted organs are being rejected.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Americas

Fed Circuit rejects Stanford Uni’s ‘abstract’ genetics patent

15 March 2021 Stanford University can’t patent a genetic testing method as it is based on “abstract mathematical calculations”, the US Court of Appeals for the Federal Circuit has ruled.

Americas

CareDx drops transplant testing patent suit

3 September 2020 California-based molecular diagnostics company CareDx and Stanford University have dropped their patent infringement suit against Tai Diagnostics, nearly five months after filing the complaint.

Big Pharma

Natera sues ArcherDX for oncology patent infringement

29 January 2020 DNA testing developer Natera is suing ArcherDX, a molecular technology company, for allegedly infringing a patent related to multiplex polymerase chain reaction technology.

More features

Killing the golden goose of US drug innovation (Part II): Drug pricing myths

Former pharma GC brings in-house perspective to McGuireWoods

Sandoz eyes US biosimilar launch as Regeneron settles

Killing the golden goose of US drug innovation (Part I): Follow the money

Buchalter brings in new partner to head up medtech

Trump’s march-in rights threat: Why pharma is rethinking collaborations

UK gets new IP minister following cabinet reshuffle

Barnes & Thornburg reveals five new IP leaders

Stanford sues Natera over transplant testing patents

More on this story

Editor's picks

Editor's picks

More features